Helix BioPharma Corp. faces a challenging day in the market as its stock price takes a hit.
Helix BioPharma Corp. (HBP.TO) is experiencing a downturn today, with its stock price falling by 2.10% to close at CA$1.40. This decline raises concerns among investors about the company's financial stability and future prospects.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$109.22M
52W high
$5.40
52W low
$0.95
1W change
-2.78%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 78.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+78.6% Upside
Current Price
C$1.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
53.1%
Annualized
90-Day Vol
70.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.17
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.32 | C$1.10 โ C$1.58 |
| 60 trading days | C$1.24 | C$0.96 โ C$1.61 |
| 90 trading days | C$1.17 | C$0.85 โ C$1.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Helix BioPharma's financial health and strategic plans, especially in light of today's stock performance.
Helix BioPharma Corp. Market Cap
With a market cap of CA$109.22 million, Helix BioPharma's stock is under pressure amid investor uncertainty.
Bull case
If Helix BioPharma can secure the necessary financing to advance its projects, it may regain investor confidence and drive future growth.
Bear case
Ongoing financial instability and a lack of significant news could further erode investor trust, leading to more declines in the stock price.
Market Performance Overview
Today, Helix BioPharma Corp. (HBP.TO) saw its stock price drop by 2.10%. This decline may reflect investor concerns regarding the company's financial stability, especially in the absence of significant news or updates.
Investor Sentiment
With a market cap of CA$109.22 million, the current downturn raises questions about Helix BioPharma's ability to attract investment. Investors are advised to keep an eye on upcoming financial results and strategic announcements that could impact the stock's trajectory. For more details on the company's financials, check out the Helix BioPharma Corp. stock page.
Future Outlook
As Helix BioPharma continues to navigate its financial landscape, the potential for recovery hinges on its ability to secure funding and advance its projects. Investors should remain vigilant and consider the implications of today's performance on future investments.
Advertisement
